Detalhe da pesquisa
1.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115523
2.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
J Am Acad Dermatol
; 88(1): 29-39, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820547
3.
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
Immunotherapy
; 15(12): 963-973, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150952
4.
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Immunotherapy
; 15(11): 787-797, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150956
5.
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(4): 442-453, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35182043
6.
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Dermatol Ther (Heidelb)
; 11(5): 1763-1776, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34471993
7.
Population Pharmacokinetic Analysis of BMS-986166, a Novel Selective Sphingosine-1-Phosphate-1 Receptor Modulator, and Exposure-Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants.
Clin Pharmacol Drug Dev
; 10(1): 8-21, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090733
8.
The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants.
Expert Opin Investig Drugs
; 29(4): 411-422, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32306792
9.
Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing.
Clin Pharmacol Drug Dev
; 9(6): 689-698, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068354
10.
Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma.
Front Pharmacol
; 4: 54, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23641215
11.
Biochemical characterization of the first essential two-component signal transduction system from Staphylococcus aureus and Streptococcus pneumoniae.
J Mol Microbiol Biotechnol
; 5(4): 252-60, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12867749